Comprehensive Medicinal Chemistry III

Samuel Chackalamannil, David Rotella, Simon E. Ward

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

Biopharmaceuticals are now becoming an innovative strategy for developing new therapeutic agents. The field of biologics medicine is expanding into new areas of molecular diversity, which comprises polypeptides, oligonucleotides (DNA, siRNA, microRNA), antibodies (monoclonal and conjugated antibodies), and PNA (peptide nucleic acid) structures. The aim of introducing biologics medicine to the Comprehensive Medicinal Chemistry series is to present an overview of different large molecule drug modalities and the innovative science and challenges involved in developing biologics-based medicine. Biopharmaceuticals are in an earlier stage of development relative to small molecules, but the field is progressing exponentially. Advances in the basic science and application of technologies related to DNA/RNA heteroduplex oligonucleotide, antisense oligonucleotide (ASO) mRNA/protein, and transformative heterodimeric IgG bispecific antibodies including clinical evaluation of drug candidates in the field are accelerating.

Original languageEnglish
Title of host publicationThe Future of Drug Discovery
Subtitle of host publicationDrug Discovery Technologies: In Silico Drug Discovery Tools: Experimental Adme and Toxicology: Cancer, Immunology and Inflammation, and Infectious Disease: Biologics Medicine: Cns, Pain, Metabolic Syndrome, Cardiovascular, Tissue Fibrosis and Urinary Incontinence: Case Histories in Recent Drug Discovery
PublisherElsevier Inc.
Pages1-4369
Number of pages4369
Volume1-8
ISBN (Electronic)9780128032008
ISBN (Print)9780128032015
StatePublished - 3 Jun 2017

Fingerprint

Biological Products
Medicine
Bispecific Antibodies
Peptide Nucleic Acids
Molecules
Antisense Oligonucleotides
Oligonucleotides
DNA
MicroRNAs
Pharmaceutical Preparations
Small Interfering RNA
Immunoglobulin G
Monoclonal Antibodies
RNA
Messenger RNA
Peptides
Antibodies
Pharmaceutical Chemistry
Proteins

Cite this

Chackalamannil, S., Rotella, D., & Ward, S. E. (2017). Comprehensive Medicinal Chemistry III. In The Future of Drug Discovery: Drug Discovery Technologies: In Silico Drug Discovery Tools: Experimental Adme and Toxicology: Cancer, Immunology and Inflammation, and Infectious Disease: Biologics Medicine: Cns, Pain, Metabolic Syndrome, Cardiovascular, Tissue Fibrosis and Urinary Incontinence: Case Histories in Recent Drug Discovery (Vol. 1-8, pp. 1-4369). Elsevier Inc..
Chackalamannil, Samuel ; Rotella, David ; Ward, Simon E. / Comprehensive Medicinal Chemistry III. The Future of Drug Discovery: Drug Discovery Technologies: In Silico Drug Discovery Tools: Experimental Adme and Toxicology: Cancer, Immunology and Inflammation, and Infectious Disease: Biologics Medicine: Cns, Pain, Metabolic Syndrome, Cardiovascular, Tissue Fibrosis and Urinary Incontinence: Case Histories in Recent Drug Discovery. Vol. 1-8 Elsevier Inc., 2017. pp. 1-4369
@inbook{1d942d54b4c34a9183e5882498366dc2,
title = "Comprehensive Medicinal Chemistry III",
abstract = "Biopharmaceuticals are now becoming an innovative strategy for developing new therapeutic agents. The field of biologics medicine is expanding into new areas of molecular diversity, which comprises polypeptides, oligonucleotides (DNA, siRNA, microRNA), antibodies (monoclonal and conjugated antibodies), and PNA (peptide nucleic acid) structures. The aim of introducing biologics medicine to the Comprehensive Medicinal Chemistry series is to present an overview of different large molecule drug modalities and the innovative science and challenges involved in developing biologics-based medicine. Biopharmaceuticals are in an earlier stage of development relative to small molecules, but the field is progressing exponentially. Advances in the basic science and application of technologies related to DNA/RNA heteroduplex oligonucleotide, antisense oligonucleotide (ASO) mRNA/protein, and transformative heterodimeric IgG bispecific antibodies including clinical evaluation of drug candidates in the field are accelerating.",
author = "Samuel Chackalamannil and David Rotella and Ward, {Simon E.}",
year = "2017",
month = "6",
day = "3",
language = "English",
isbn = "9780128032015",
volume = "1-8",
pages = "1--4369",
booktitle = "The Future of Drug Discovery",
publisher = "Elsevier Inc.",

}

Chackalamannil, S, Rotella, D & Ward, SE 2017, Comprehensive Medicinal Chemistry III. in The Future of Drug Discovery: Drug Discovery Technologies: In Silico Drug Discovery Tools: Experimental Adme and Toxicology: Cancer, Immunology and Inflammation, and Infectious Disease: Biologics Medicine: Cns, Pain, Metabolic Syndrome, Cardiovascular, Tissue Fibrosis and Urinary Incontinence: Case Histories in Recent Drug Discovery. vol. 1-8, Elsevier Inc., pp. 1-4369.

Comprehensive Medicinal Chemistry III. / Chackalamannil, Samuel; Rotella, David; Ward, Simon E.

The Future of Drug Discovery: Drug Discovery Technologies: In Silico Drug Discovery Tools: Experimental Adme and Toxicology: Cancer, Immunology and Inflammation, and Infectious Disease: Biologics Medicine: Cns, Pain, Metabolic Syndrome, Cardiovascular, Tissue Fibrosis and Urinary Incontinence: Case Histories in Recent Drug Discovery. Vol. 1-8 Elsevier Inc., 2017. p. 1-4369.

Research output: Chapter in Book/Report/Conference proceedingChapter

TY - CHAP

T1 - Comprehensive Medicinal Chemistry III

AU - Chackalamannil, Samuel

AU - Rotella, David

AU - Ward, Simon E.

PY - 2017/6/3

Y1 - 2017/6/3

N2 - Biopharmaceuticals are now becoming an innovative strategy for developing new therapeutic agents. The field of biologics medicine is expanding into new areas of molecular diversity, which comprises polypeptides, oligonucleotides (DNA, siRNA, microRNA), antibodies (monoclonal and conjugated antibodies), and PNA (peptide nucleic acid) structures. The aim of introducing biologics medicine to the Comprehensive Medicinal Chemistry series is to present an overview of different large molecule drug modalities and the innovative science and challenges involved in developing biologics-based medicine. Biopharmaceuticals are in an earlier stage of development relative to small molecules, but the field is progressing exponentially. Advances in the basic science and application of technologies related to DNA/RNA heteroduplex oligonucleotide, antisense oligonucleotide (ASO) mRNA/protein, and transformative heterodimeric IgG bispecific antibodies including clinical evaluation of drug candidates in the field are accelerating.

AB - Biopharmaceuticals are now becoming an innovative strategy for developing new therapeutic agents. The field of biologics medicine is expanding into new areas of molecular diversity, which comprises polypeptides, oligonucleotides (DNA, siRNA, microRNA), antibodies (monoclonal and conjugated antibodies), and PNA (peptide nucleic acid) structures. The aim of introducing biologics medicine to the Comprehensive Medicinal Chemistry series is to present an overview of different large molecule drug modalities and the innovative science and challenges involved in developing biologics-based medicine. Biopharmaceuticals are in an earlier stage of development relative to small molecules, but the field is progressing exponentially. Advances in the basic science and application of technologies related to DNA/RNA heteroduplex oligonucleotide, antisense oligonucleotide (ASO) mRNA/protein, and transformative heterodimeric IgG bispecific antibodies including clinical evaluation of drug candidates in the field are accelerating.

UR - http://www.scopus.com/inward/record.url?scp=85041583558&partnerID=8YFLogxK

M3 - Chapter

AN - SCOPUS:85041583558

SN - 9780128032015

VL - 1-8

SP - 1

EP - 4369

BT - The Future of Drug Discovery

PB - Elsevier Inc.

ER -

Chackalamannil S, Rotella D, Ward SE. Comprehensive Medicinal Chemistry III. In The Future of Drug Discovery: Drug Discovery Technologies: In Silico Drug Discovery Tools: Experimental Adme and Toxicology: Cancer, Immunology and Inflammation, and Infectious Disease: Biologics Medicine: Cns, Pain, Metabolic Syndrome, Cardiovascular, Tissue Fibrosis and Urinary Incontinence: Case Histories in Recent Drug Discovery. Vol. 1-8. Elsevier Inc. 2017. p. 1-4369